Boehringer Navigates ‘Impractical’ Nintedanib Surveillance Plan In India

 
• By Anju Ghangurde
  
Compliance
BOEHRINGER HAS SOUGHT TWEAKS IN UNVIABLE PMS REQUIREMENTS FOR NINTEDANIB
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Review Pathways

More from Pathways & Standards